J. Usary

发表

CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis.

Charles M Perou, Matthew D. Smith, Feng Bai, 2009, Cancer cell.

Comprehensive molecular portraits of human breast tumors

Steven J. M. Jones, Andrew H. Beck, Joshua F. McMichael, 2012, Nature.

Mutation of GATA3 in human breast tumors

R. Strausberg, C. Perou, P. Lønning, 2004, Oncogene.

Proteogenomic integration reveals therapeutic targets in breast cancer xenografts

Li Ding, David Fenyö, Jason M Held, 2017, Nature Communications.

c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer

C. Perou, S. Lakhani, S. O'toole, 2014, Oncogene.

BMC Genomics BioMed Central Methodology article Universal Reference RNA as a standard for microarray experiments

David Botstein, Alexey Novoradovsky, Charles M Perou, 2004 .

Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models

James S. Duncan, C. Perou, David B. Darr, 2012, Clinical Cancer Research.

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

Zhiyuan Hu, Charles M Perou, Jason I. Herschkowitz, 2007, Genome Biology.

Characterization of 50S Ribosomal Subunit Assembly Inhibition in Erythromycin Treated Escherichia coli Cells.

J. Usary, 2000 .

Erythromycin inhibition of 50S ribosomal subunit formation in Escherichia coli cells

J. Usary, W. S. Champney, Jerry E. Usary, 2001, Molecular microbiology.

Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.

Charles M. Perou, Kwok-Kin Wong, William C. Zamboni, 2012, Journal of the National Cancer Institute.

Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer.

C. Perou, R. Cardiff, Vicki Ling, 2012, Cancer cell.

A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer

C. Perou, David B. Darr, J. Usary, 2018, Breast Cancer Research and Treatment.

Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells

Jason I. Herschkowitz, C. Perou, S. Hilsenbeck, 2011, Proceedings of the National Academy of Sciences.

Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer

Jian Jin, Charles M. Perou, Katherine A. Hoadley, 2012, Cell.

Dietary Energy Balance Modulates Epithelial-to-Mesenchymal Transition and Tumor Progression in Murine Claudin-Low and Basal-like Mammary Tumor Models

C. Perou, L. Varticovski, J. Usary, 2012, Cancer Prevention Research.

Targeting the PyMT Oncogene to Diverse Mammary Cell Populations Enhances Tumor Heterogeneity and Generates Rare Breast Cancer Subtypes.

C. Perou, P. Bernard, D. Shelton, 2012, Genes & cancer.

Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice

C. Perou, M. Cheang, Wei Zhao, 2013, Clinical Cancer Research.

Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts

Jason I. Herschkowitz, G. Wahl, C. Perou, 2013, Genome Biology.

Bryan Generates Rare Breast Cancer Subtypes Targeting the PyMT Oncogene to Diverse Mammary Cell Populations Enhances Tumor Heterogeneity and

C. Perou, P. Bernard, D. Shelton, 2013 .

Department of Pathology, Thomas Jefferson University, Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

Jason I. Herschkowitz, Karen E. Rasmussen, C. Perou, 2020 .

Department of Pathology, Thom as Jeffe rson University, Identific ation of conserved gene expression features between murine mammary carcinoma models and human breast tumors.

Jason I. Herschkowitz, Karen E. Rasmussen, C. Perou, 2007 .

Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes

C. Perou, David B. Darr, J. Usary, 2016, Current protocols in pharmacology.

Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule

C. Perou, Hong Wang, L. Carey, 2017, npj Precision Oncology.

Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.

Zhiyuan Hu, Charles M Perou, Melissa A Troester, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metabolic reprogramming underlies metastatic potential in an obesity-responsive murine model of metastatic triple negative breast cancer

C. Perou, J. Parker, J. Usary, 2017, npj Breast Cancer.

Corrigendum: Proteogenomic integration reveals therapeutic targets in breast cancer xenografts

Sam Q. Sun, Adam D. Scott, Matthew A. Wyczalkowski, 2017, Nature Communications.

Cancer Therapy : Preclinical Combined PI 3 K / mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models

James S. Duncan, C. Perou, David B. Darr, 2012 .

Mutation of GATA 3 in human breast tumors

R. Strausberg, C. Perou, S. Chanock, 2004 .

The Role of Calcineurin/NFAT in SFRP2 Induced Angiogenesis—A Rationale for Breast Cancer Treatment with the Calcineurin Inhibitor Tacrolimus

Cam Patterson, David B. Darr, Eleanor G. Hilliard, 2011, PloS one.

Differential response to exercise in claudin-low breast cancer

M. Dewhirst, David B. Darr, L. Jones, 2017, Oncotarget.

Metabolic reprogramming underlies metastatic potential in an obesity-responsive murine model of metastatic triple negative breast cancer

C. Perou, J. Parker, J. Usary, 2017, npj Breast Cancer.

Comprehensive molecular portraits of human breast tumours

Steven J. M. Jones, Joshua F. McMichael, Joshua M. Stuart, 2013 .